Millennium Capital Advisors LLC Makes New $2.71 Million Investment in AbbVie Inc. $ABBV

Millennium Capital Advisors LLC purchased a new position in AbbVie Inc. (NYSE:ABBV) during the 4th quarter, HoldingsChannel reports. The firm purchased 11,875 shares of the company’s stock, valued at approximately $2,713,000. AbbVie makes up 1.6% of Millennium Capital Advisors LLC’s investment portfolio, making the stock its 13th largest holding.

Several other institutional investors also recently added to or reduced their stakes in the business. Canada Post Corp Registered Pension Plan increased its position in AbbVie by 17.2% in the 4th quarter. Canada Post Corp Registered Pension Plan now owns 60,412 shares of the company’s stock worth $13,804,000 after buying an additional 8,880 shares during the period. Cambridge Investment Research Advisors Inc. increased its position in AbbVie by 1.8% in the 4th quarter. Cambridge Investment Research Advisors Inc. now owns 545,217 shares of the company’s stock worth $124,577,000 after buying an additional 9,761 shares during the period. Hills Bank & Trust Co increased its position in AbbVie by 14.7% in the 4th quarter. Hills Bank & Trust Co now owns 6,141 shares of the company’s stock worth $1,403,000 after buying an additional 789 shares during the period. Everstar Asset Management LLC increased its position in AbbVie by 1.6% in the 4th quarter. Everstar Asset Management LLC now owns 4,745 shares of the company’s stock worth $1,084,000 after buying an additional 73 shares during the period. Finally, Lawood & Co. bought a new position in AbbVie in the 4th quarter worth approximately $2,869,000. 70.23% of the stock is owned by institutional investors.

AbbVie News Summary

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie’s Q1 results were supported by strong sales of Skyrizi and Rinvoq, which helped offset ongoing Humira declines and boosted the company’s 2026 guidance. Article: How Important Are Skyrizi and Rinvoq to AbbVie’s Q1 Results?
• Positive Sentiment: Analysts have turned more optimistic on AbbVie’s earnings power, with Erste Group raising FY2027 EPS estimates and the company’s long-term pipeline still viewed favorably.
• Positive Sentiment: Recent commentary highlighted AbbVie as a potentially better growth story than AstraZeneca because of its valuation, dividend profile, and pipeline strength. Article: Which Pharma Giant Offers Better Growth: AstraZeneca or AbbVie?

AbbVie Trading Down 0.1%

Shares of NYSE:ABBV opened at $210.54 on Friday. AbbVie Inc. has a 1-year low of $180.25 and a 1-year high of $244.81. The firm has a market capitalization of $371.98 billion, a PE ratio of 103.71, a PEG ratio of 0.73 and a beta of 0.32. The business’s 50 day moving average is $210.27 and its 200-day moving average is $220.10.

AbbVie (NYSE:ABBV) last announced its quarterly earnings data on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. During the same quarter last year, the firm earned $2.46 EPS. AbbVie’s revenue for the quarter was up 12.4% compared to the same quarter last year. On average, sell-side analysts predict that AbbVie Inc. will post 14.3 EPS for the current year.

AbbVie Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th were issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 3.3%. The ex-dividend date of this dividend was Wednesday, April 15th. AbbVie’s dividend payout ratio (DPR) is presently 340.89%.

Analyst Ratings Changes

ABBV has been the topic of several recent analyst reports. Berenberg Bank set a $275.00 price target on AbbVie in a research report on Tuesday, January 20th. UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating on the stock in a research report on Thursday, February 5th. Evercore set a $235.00 price target on AbbVie in a research report on Friday. William Blair reaffirmed an “outperform” rating on shares of AbbVie in a research report on Monday, March 9th. Finally, Bank of America raised AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 price target on the stock in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat, AbbVie presently has a consensus rating of “Moderate Buy” and an average target price of $253.43.

Insider Activity at AbbVie

In related news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the sale, the executive vice president owned 38,137 shares of the company’s stock, valued at $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president directly owned 2,654 shares in the company, valued at approximately $619,868.24. This represents a 66.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.06% of the stock is currently owned by company insiders.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.